Dr Suzanne Saffie-Siebert

Chairwoman & Chief Executive Officer

Suzanne is the Founder of SiSaf Ltd and inventor of ProSilic®, the company’s proprietary drug delivery platform technology. She has over 25 years of diversified pharmaceutical industry experience with an impressive record of moving pharmaceutical pipelines to commercial success. Suzanne’s broad experience in the pharmaceutical industry includes senior leadership positions in areas of research and development, manufacturing, clinical trial, quality control, business development and operations. Her previous positions include Director of Research at pSiMedica Ltd (spin out from QinetiQ) and Head of the Drug Delivery Centre at Dompé SpA (Italy). Suzanne is one of the pioneers of silicon based drug delivery and is inventor or co-inventor of several drug delivery patents. She earned her PhD from the School of Pharmacy at the University of London and is Visiting Professor at Ulster University. She also obtained a Business in Bioscience Diploma from Oxford Brookes University Business School.

Dr. Elkhalil Binebine

Khalil is Vice Chairman of Vickers Venture Partners and brings a wealth of international experience and a wide network of global contacts to SiSaf.

Prior to entering the world of finance, Khalil was a practicing M.D. in New York. He served as the personal physician to Malcolm Forbes, who was instrumental in assisting him in developing his contacts and gaining experience as an investor. In 1991, Khalil founded Gibraltar Enterprises, Inc., a global real estate investment firm and since 1996, he has represented investment funds including Carlyle, Central Partners and Castle Harbor. He joined Vickers in 2005.

Dr. Binebine graduated from the University of Bordeaux and earned an M.D. from La Sorbonne. He is a member of the Arab Banking Association of North America.

Eric Attias

Eric founded EXEN Capital, a family office, in 2014, and has 25 years of expertise in asset management, private equity and money management.

Eric previously served as CEO of Société Générale Asset Management, Inc. (SGAM), and CEO of SGAM Newedge Inc. (wholly owned subsidiaries of French banking group Société Générale). In 2009, he co-founded Nexar Capital, a global asset manager, and served as its Chief Investment Officer and as Chief Executive Officer of Nexar LLC. Following the acquisition, in 2012, of Nexar Capital by Swiss banking group UBP, Eric was appointed Chief Executive Officer of UBP Asset Management LLC and Chief Investment Officer of UBP AI. Prior to SGAM , Eric held senior money management positions at various investment banks.

Eric was educated in New York, London and Paris. He holds graduate degrees in Mathematics & Computer Science and an M.B.A from Columbia University.

Neil Simms

Neil is Finance Director and Investment Manager at Clarendon Fund Managers Ltd, who manage Co-Fund NI. Over a 15 year period he has either led or been heavily involved in negotiating and completing multiple investment rounds and exits in over twenty Northern Ireland based SMEs, across a broad range of sectors and he represents the Funds’ interests on the boards of several portfolio companies.

These include a number of innovative and successful med-tech companies, such as Cirdan Imaging Ltd, and previously, Heartsine Technologies Inc. (acquired by Physio-Control Inc. in September 2015) and Path XL Ltd (acquired by Philips in June 2016).

Neil has a BSc (Hons) in Economics and Econometrics from Nottingham University and is a member of the Institute of Chartered Accountants in Ireland, having trained and qualified with Ernst & Young in Belfast.

Tim Brundle

Tim is Director of Research & Innovation at Ulster University. He directs the university’s research strategy, governance and administration, and guides its commercial output through knowledge transfer and intellectual property commercialisation.

Tim also holds the position of Executive Director of Innovation Ulster Ltd, Ulster’s venturing and investment company. He has led the establishment of more than 35 tech start-ups, secured over £380m of Venture Capital, managed a profitable investment fund and ensured investor value from company acquisitions and a stock market flotation. He has been serving as Director of many of Ulster University’s spin out companies, Invest NI, and the UK Knowledge Transfer Network.